A prospective, randomized, three arm, open label study comparing the safety and efficacy of PP110, a novel treatment for hemorrhoids to preparation-H® maximum strength cream in the treatment of grade 2–3 hemorrhoids

  • Ehud Klein
  • Ron Shapiro
  • Jose Ben-Dahan
  • Moshe Simcha
  • Yosef Azuri
  • Ada Rosen
Keywords: Hemorrhoids, PP110, Preparation-H

Abstract

Background

Hemorrhoids are a common disorder that affects the quality of life of millions of people worldwide. The effectiveness of OTC medication is limited and they mainly provide symptomatic relief. In order to treat this ailment, we formulated PP110 Gel and Wipes, as a novel treatment for hemorrhoids. PP110 is based on known active ingredients with a topical film-forming agent designed to provide physical protection and prolonged tissue contact with the active ingredients.

Methods

PP110 Gel, PP110 Wipes and the comparator Preparation-H® were used on three patient cohorts. Treatment was administered once daily for PP110, and three-four times daily for Preparation-H®, for 14 days. Six different clinical parameters relating to common symptoms of hemorrhoids were monitored.

Results

PP110 Gel was significantly better than Preparation-H® in reducing bleeding (Δ = 6 %), providing pain relief (Δ = 10 %) and controlling itching (Δ = 11 %). These three parameters are considered as the most common distressing symptoms for hemorrhoids patients, demonstrating that PP110 is superior to conventional treatment.

Conclusion

This study demonstrated the efficacy of the PP110 Gel in treating hemorrhoids and its superiority to conventional treatments. The PP110 film-based formulation provides a slow-release mechanism and as a consequence, a prolonged therapeutic window. PP110 was both more effective in reducing hemorrhoids symptoms and more convenient to use, in that it only required application once per day.

Downloads

Download data is not yet available.

References

Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18:2009–17.

PubMedCentralCrossRefPubMedGoogle Scholar

Riss S, Weiser FA, Schwameis K, Riss T, Mittlböck M, Steiner G, et al. The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012;27:215–20.

CrossRefPubMedGoogle Scholar

Acheson AG, Scholefield JH. Management of haemorrhoids. BMJ. 2008;336:380–3.

PubMedCentralCrossRefPubMedGoogle Scholar

Riss S, Weiser FA, Riss T, Schwameis K, Mittlböck M, Stift A. Haemorrhoids and quality of life. Colorectal Dis. 2011;13:e48–52.

CrossRefPubMedGoogle Scholar

Barnert J, Messmann H. Diagnosis and management of lower gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol. 2009;6:637–46.

CrossRefPubMedGoogle Scholar

Gazet JC, Redding W, Rickett JW. The prevalence of haemorrhoids. A preliminary survey. Proc R Soc Med. 1970;63:78–80.

PubMedCentralPubMedGoogle Scholar

Nisar PJ, Scholefield JH. Managing haemorrhoids. BMJ. 2003;327:847–51.

PubMedCentralCrossRefPubMedGoogle Scholar

Anderson JW, Baird P, Davis RH, Ferreri S, Knudtson M, Koraym A, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67:188–205.

CrossRefPubMedGoogle Scholar

Hall JF. Modern management of hemorrhoidal disease. Gastroenterol Clin North Am. 2013;42:759–72.

CrossRefPubMedGoogle Scholar

Song SG, Kim SH. Optimal treatment of symptomatic hemorrhoids. J Korean Soc Coloproctol. 2011;27:277–81.

PubMedCentralCrossRefPubMedGoogle Scholar

Wyeth History [http://www.fundinguniverse.com/company-histories/wyeth-history/].

NIH DailyMed. [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7cc03d2e-e708-589a-d9bb-58ebbda989c0].

Altomare DF, Giannini I. Pharmacological treatment of hemorrhoids: a narrative review. Expert Opin Pharmacother. 2013;14:2343–9.

CrossRefPubMedGoogle Scholar

Jacobs D. Clinical practice. Hemorrhoids. N Engl J Med. 2014;371:944–51.

CrossRefPubMedGoogle Scholar

Published
2019-02-07
Section
Research Article